Revolution Medicines Inc
RVMD78.780USD
+2.820+3.71%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
14.95BMarket Cap
LossP/E TTM
More Details of Revolution Medicines Inc Company
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
Revolution Medicines Inc Info
Ticker SymbolRVMD
Company nameRevolution Medicines Inc
IPO dateFeb 13, 2020
CEOGoldsmith (Mark A)
Number of employees534
Security typeOrdinary Share
Fiscal year-endFeb 13
Address700 Saginaw Dr
CityREDWOOD CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94063
Phone16504816801
Websitehttps://www.revmed.com/
Ticker SymbolRVMD
IPO dateFeb 13, 2020
CEOGoldsmith (Mark A)
Company Executives of Revolution Medicines Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Wei Lin, M.D.
Dr. Wei Lin, M.D.
Chief Medical Officer
Chief Medical Officer
85.28K
-2.47%
Dr. Lorence H. Kim, M.D.
Dr. Lorence H. Kim, M.D.
Independent Director
Independent Director
67.09K
+4.91%
Mr. Jeff Cislini
Mr. Jeff Cislini
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
56.49K
+48.70%
Ms. Margaret A. (Peg) Horn, J.D.
Ms. Margaret A. (Peg) Horn, J.D.
Chief Operating Officer
Chief Operating Officer
56.20K
-7.83%
Mr. Jack Lee Anders, CPA
Mr. Jack Lee Anders, CPA
Chief Financial Officer
Chief Financial Officer
50.37K
--
Ms. Xiaolin Wang
Ms. Xiaolin Wang
Executive Vice President - Development
Executive Vice President - Development
48.39K
+87.73%
Dr. Flavia Borellini, Ph.D.
Dr. Flavia Borellini, Ph.D.
Independent Director
Independent Director
20.78K
+17.82%
Dr. Sushil Patel, Ph.D.
Dr. Sushil Patel, Ph.D.
Independent Director
Independent Director
17.09K
+22.52%
Dr. Alan Sandler, M.D.
Dr. Alan Sandler, M.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Sandra J. Horning, M.D.
Dr. Sandra J. Horning, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Wei Lin, M.D.
Dr. Wei Lin, M.D.
Chief Medical Officer
Chief Medical Officer
85.28K
-2.47%
Dr. Lorence H. Kim, M.D.
Dr. Lorence H. Kim, M.D.
Independent Director
Independent Director
67.09K
+4.91%
Mr. Jeff Cislini
Mr. Jeff Cislini
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
56.49K
+48.70%
Ms. Margaret A. (Peg) Horn, J.D.
Ms. Margaret A. (Peg) Horn, J.D.
Chief Operating Officer
Chief Operating Officer
56.20K
-7.83%
Mr. Jack Lee Anders, CPA
Mr. Jack Lee Anders, CPA
Chief Financial Officer
Chief Financial Officer
50.37K
--
Ms. Xiaolin Wang
Ms. Xiaolin Wang
Executive Vice President - Development
Executive Vice President - Development
48.39K
+87.73%
Revenue Breakdown
FY2024
FY2023
FY2022
FY2021
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
8.09%
Farallon Capital Management, L.L.C.
7.57%
Janus Henderson Investors
5.87%
Wellington Management Company, LLP
5.08%
Baker Bros. Advisors LP
4.89%
Other
68.51%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
8.09%
Farallon Capital Management, L.L.C.
7.57%
Janus Henderson Investors
5.87%
Wellington Management Company, LLP
5.08%
Baker Bros. Advisors LP
4.89%
Other
68.51%
Shareholder Types
Shareholders
Proportion
Investment Advisor
39.34%
Hedge Fund
29.63%
Investment Advisor/Hedge Fund
23.46%
Venture Capital
4.58%
Individual Investor
1.88%
Private Equity
1.80%
Research Firm
1.43%
Sovereign Wealth Fund
0.88%
Pension Fund
0.57%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
593
193.98M
100.35%
-10.39M
2025Q2
569
198.78M
106.34%
-10.16M
2025Q1
578
202.67M
108.85%
-6.24M
2024Q4
550
200.50M
107.86%
+9.16M
2024Q3
508
178.03M
106.09%
-11.19M
2024Q2
474
175.13M
105.71%
-4.08M
2024Q1
450
165.87M
97.52%
-10.22M
2023Q4
413
166.29M
101.77%
+33.45M
2023Q3
369
116.05M
106.21%
-8.60M
2023Q2
358
115.90M
109.17%
-5.53M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
15.73M
8.41%
-849.90K
-5.13%
Jun 30, 2025
Farallon Capital Management, L.L.C.
14.33M
7.66%
+791.00K
+5.84%
Jun 30, 2025
Janus Henderson Investors
10.59M
5.67%
+400.66K
+3.93%
Jun 30, 2025
Wellington Management Company, LLP
10.26M
5.49%
-1.53M
-12.96%
Jun 30, 2025
Baker Bros. Advisors LP
9.36M
5.01%
+1.43M
+17.99%
Jun 30, 2025
Fidelity Management & Research Company LLC
8.32M
4.45%
+919.01K
+12.41%
Jun 30, 2025
Nextech Invest, Ltd.
7.60M
4.07%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
7.84M
4.2%
-4.94M
-38.66%
Jun 30, 2025
Paradigm BioCapital Advisors LP
6.09M
3.26%
-84.82K
-1.37%
Jun 30, 2025
Bellevue Asset Management AG
4.58M
2.45%
+205.00K
+4.69%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Tema Oncology ETF
9.9%
iShares Genomics Immunology and Healthcare ETF
5.38%
State Street SPDR S&P Biotech ETF
3.83%
Harbor Health Care ETF
2.62%
ProShares Ultra Nasdaq Biotechnology
1.77%
Tema Heart & Health ETF
1.75%
Direxion Daily S&P Biotech Bull 3X Shares
1.59%
Invesco Nasdaq Biotechnology ETF
1.07%
Virtus LifeSci Biotech Clinical Trials ETF
0.97%
iShares Biotechnology ETF
0.84%
View more
Tema Oncology ETF
Proportion9.9%
iShares Genomics Immunology and Healthcare ETF
Proportion5.38%
State Street SPDR S&P Biotech ETF
Proportion3.83%
Harbor Health Care ETF
Proportion2.62%
ProShares Ultra Nasdaq Biotechnology
Proportion1.77%
Tema Heart & Health ETF
Proportion1.75%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion1.59%
Invesco Nasdaq Biotechnology ETF
Proportion1.07%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.97%
iShares Biotechnology ETF
Proportion0.84%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Revolution Medicines Inc?
The top five shareholders of Revolution Medicines Inc are:
The Vanguard Group, Inc. holds 15.73M shares, accounting for 8.41% of the total shares.
Farallon Capital Management, L.L.C. holds 14.33M shares, accounting for 7.66% of the total shares.
Janus Henderson Investors holds 10.59M shares, accounting for 5.67% of the total shares.
Wellington Management Company, LLP holds 10.26M shares, accounting for 5.49% of the total shares.
Baker Bros. Advisors LP holds 9.36M shares, accounting for 5.01% of the total shares.
The Vanguard Group, Inc. holds 15.73M shares, accounting for 8.41% of the total shares.
Farallon Capital Management, L.L.C. holds 14.33M shares, accounting for 7.66% of the total shares.
Janus Henderson Investors holds 10.59M shares, accounting for 5.67% of the total shares.
Wellington Management Company, LLP holds 10.26M shares, accounting for 5.49% of the total shares.
Baker Bros. Advisors LP holds 9.36M shares, accounting for 5.01% of the total shares.
What are the top three shareholder types of Revolution Medicines Inc?
The top three shareholder types of Revolution Medicines Inc are:
The Vanguard Group, Inc.
Farallon Capital Management, L.L.C.
Janus Henderson Investors
The Vanguard Group, Inc.
Farallon Capital Management, L.L.C.
Janus Henderson Investors
How many institutions hold shares of Revolution Medicines Inc (RVMD)?
As of 2025Q3, 593 institutions hold shares of Revolution Medicines Inc, with a combined market value of approximately 193.98M, accounting for 100.35% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -5.99%.
What is the biggest source of revenue for Revolution Medicines Inc?
In FY2024, the -- business generated the highest revenue for Revolution Medicines Inc, amounting to -- and accounting for --% of total revenue.
